{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T19:13:50Z","timestamp":1773170030614,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejca.2018.01.088","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T13:49:39Z","timestamp":1519220979000},"page":"104-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Dose-dependent toxicity of ipilimumab in metastatic melanoma"],"prefix":"10.1016","volume":"95","author":[{"given":"Alexandra","family":"Olischewsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"De Schrijver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Wetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.01.088_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"8","key":"10.1016\/j.ejca.2018.01.088_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.01.088_bib3","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.01.088_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2017.06.021","article-title":"Risk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysis","volume":"83","author":"Zhang","year":"2017","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.ejca.2018.01.088_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.01.088_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/cbr.2010.0865","article-title":"Releasing the brake on the immune system: ipilimumab in melanoma and other tumors","volume":"25","author":"Tarhini","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ejca.2018.01.088_bib7","first-page":"215","article-title":"Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma","volume":"36","author":"Wilgenhof","year":"2013","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"5","key":"10.1016\/j.ejca.2018.01.088_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.01.088_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.01.088_bib10","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.01.088_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.01.088_bib12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.01.088_bib13","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1200\/JCO.2017.35.15_suppl.9500","article-title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms","volume":"35","author":"Tarhini","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.01.088_bib14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-017-3444-0","article-title":"Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab","volume":"80","author":"Nomura","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2018.01.088_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2018.01.088_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918301229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918301229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T08:57:16Z","timestamp":1570784236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918301229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":16,"alternative-id":["S0959804918301229"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.01.088","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent toxicity of ipilimumab in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.01.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}